Biotechnology company Roche (SIX: RO, ROG) (OTCQX: RHHBY) announced on Monday that it has expanded its digital pathology open environment by integrating over 20 new artificial intelligence (AI) algorithms from eight new collaborators. These partnerships aim to support pathologists and scientists in advancing cancer research and diagnosis, enhancing precision medicine through targeted treatments.

This integration is facilitated through Roche's navify Digital Pathology software, which now offers a wider range of AI tools to improve pathology insights.

Collaborators include Deep Bio, DiaDeep, Lunit, Mindpeak, Owkin, Qritive, Sonrai Analytics and Stratipath, each contributing specialised algorithms for various cancer types such as prostate, breast, lung and colorectal cancers.

Roche, a leader in digital pathology solutions, continues its commitment to personalised healthcare by incorporating innovative AI-driven diagnostics into routine clinical practice.